{"product_id":"memorial-sloan-kettering-cancer-center-oncologic-toxicity-management-symposium-2025","title":"Memorial Sloan Kettering Cancer Center Oncologic Toxicity Management Symposium 2025","description":"\u003ch3\u003eMemorial Sloan Kettering Cancer Center Oncologic Toxicity Management Symposium 2025\u003c\/h3\u003e\n\u003cstrong\u003eInclude: 27 videos + 24 pdfs, size: 3.55 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: oncologists, hematologists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eInformation:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003eDate \u0026amp; Location: Friday, June 20, 2025, 8:00 AM – 6:00 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cem\u003eSpecialties\u003c\/em\u003e – Allergy and Immunology, Cardiology, Dermatology, Dermatopathology, Emergency Medicine, Endocrinology, Diabetes and Metabolism, Gastroenterology, Gastrointestinal Oncology, Genitourinary Oncology, Geriatric Medicine, Gynecologic Oncology, Immunotherapy, Integrative Medicine, Medical Oncology, Neurology, Neuro-Oncology, Nurse Practitioner, Rheumatology, Solid Tumor Oncology\u003c\/div\u003e\n\u003ch3\u003eOverview\u003c\/h3\u003e\u003cbr\u003eThe \u003cstrong\u003e2025 Oncology Toxicity Management Symposium\u003c\/strong\u003e unites leading oncologists, researchers, and healthcare professionals to explore the latest breakthroughs in cancer treatment and toxicity management. With rapid advancements in oncology, this symposium serves as a critical platform for discussing emerging therapies, their clinical applications, and strategies to mitigate treatment-related adverse events, ultimately aiming to improve patient care and outcomes.\u003cbr\u003e\u003cbr\u003eAs oncology continues to evolve, new therapies are revolutionizing the landscape of cancer treatment. This symposium will provide a comprehensive, evidence-based approach to understanding next-generation treatments, their efficacy, and the challenges associated with their implementation in clinical practice.\u003cbr\u003e\u003cbr\u003eAttendees will gain deep insights into the mechanisms, benefits, and risks of cutting-edge therapies, including:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eRadioligand Therapy\u003c\/strong\u003e – A novel approach that delivers targeted radiation to cancer cells, offering precise treatment with minimal damage to surrounding tissues. The session will focus on clinical applications, effectiveness, and strategies to manage radiation-related toxicity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntibody Drug Conjugates (ADCs)\u003c\/strong\u003e – A breakthrough class of targeted cancer therapies designed to deliver highly potent chemotherapy directly to cancer cells. Experts will discuss the latest ADC developments, clinical benefits, and effective management of associated toxicities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCAR-T Cell Therapy\u003c\/strong\u003e – A groundbreaking immunotherapy that harnesses the body’s own immune system to fight cancer. This session will address treatment protocols and management of adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBispecific Antibodies\u003c\/strong\u003e – A cutting-edge approach that redirects T-cells to attack tumor cells. Attendees will gain an understanding of the potential of Bispecific Antibodies, their clinical applications, and how to mitigate immune-related toxicities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSmall Molecule Inhibitors (SMIs)\u003c\/strong\u003e – Targeted agents that block key pathways involved in cancer growth. This session will explore the role of SMIs in oncology, their therapeutic potential, and management of associated risks such as cardiovascular toxicity and metabolic disturbances.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmune Checkpoint Inhibitors (ICIs)\u003c\/strong\u003e – A revolutionary class of immunotherapies that enhance the body’s natural ability to fight cancer. Experts will discuss how ICIs are reshaping oncology, the challenges of immune-related adverse events (irAEs), and best practices for toxicity management.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003eThrough expert-led presentations, panel discussions, and interactive Q\u0026amp;A sessions, attendees will deepen their understanding of novel therapies transforming oncology care, learn strategies to manage treatment-related toxicities, engage with thought leaders on cutting-edge research and clinical trials, and connect with peers to foster innovation in cancer treatment.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTarget Audience\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eThis symposium is an essential event for oncologists, hematologists, researchers, nurse practitioners, physician assistants, pharmacists, and all healthcare professionals involved in cancer care. Attendees will leave with actionable knowledge and practical tools to optimize patient outcomes and stay at the forefront of oncology advancements.\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eObjectives\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003eAt the conclusion of this symposium, attendees will be able to:\u003c\/div\u003e\n\u003col\u003e\n\u003cli\u003eDescribe the mechanism of action, indications, and clinical efficacy of Radioligand Therapy, Antibody Drug Conjugates (ADCs), Bispecific Antibodies, CAR-T Cell Therapy, Small Molecule Inhibitors (SMIs), and Immune Checkpoint Inhibitors (ICIs).\u003c\/li\u003e\n\u003cli\u003eDevelop evidence-based strategies to identify, prevent, and manage treatment-related toxicities, such as cytokine release syndrome (CRS), neurotoxicity, immune-related adverse events (irAEs), and organ-specific toxicities.\u003c\/li\u003e\n\u003cli\u003eRecognize the early signs of adverse reactions and implement effective interventions to reduce complications and improve patient safety.\u003c\/li\u003e\n\u003cli\u003eApply clinical case studies and expert insights to make informed, patient-centered decisions in oncology treatment planning.\u003c\/li\u003e\n\u003cli\u003eDiscuss how to balance treatment efficacy with toxicity management to optimize long-term patient outcomes.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cstrong\u003eTopics:\u003c\/strong\u003e\n\u003cbr\u003e\u003ch3 class=\"boxAgendaTitle\"\u003eFriday, June 20, 2025\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e8:10AM – 8:55AM Enhancing the Selectivity of RLT for Future Treatments and Trials Michael J. Morris , MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e9:00AM – 9:15AM HER2-ADCs Eleni Stavrou, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e9:15AM – 9:30AM TROP-2 ADCs Jie Chi, MD, Assistant Attending\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e9:30AM – 9:45AM NECTIN-4 ADCs Gopakumar Iyer, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e9:45AM – 10:00AM Hematologic Malignancies and ADCs Nisha Joseph, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e10:00AM – 10:15AM Management of Dermatological Adverse Events with ADCs Allison Gordon, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e10:15AM – 10:30AM Antibody Drug Conjugates (ADCs) Panel Discussion\/Q\u0026amp;A Neil Shah, MD (Moderator)\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e10:45AM – 11:00AM Bispecific Antibodies for Small Cell Cancers— DLL3 and Beyond Alissa Cooper, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e11:15AM – 11:30AM Bispecific Antibodies for Leukemia and Lymphoma Suchita Sundaram, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e11:30AM – 11:45AM Bispecific Antibodies for Multiple Myeloma Carlyn Tan, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e11:45AM – 12:00PM Bispecific Antibodies Panel Discussion\/Q\u0026amp;A Urvi Shah , MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e1:00PM – 1:15PM Immune Effector Cell (IEC) Toxicities in Solid Tumor Geoffrey Ku, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e1:15PM – 1:30PM CAR-T for Myeloma Doris Hansen, MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e1:30PM – 1:45PM CAR-T for Lymphoma Gunjan Shah , MD, MS\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e1:45PM – 2:00PM CAR-T for Leukemia Mark B Geyer , MD\u003c\/li\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e2:00PM – 2:15PM Managent of Graft vs. Host Disease and Other CAR-T Adverse Events Gagan Raju , MD, MD\u003c\/li\u003e\n\u003cli\u003e2:15PM – 2:30PM Management of Neurotoxicity with Oncology Agents Bianca D. Santomasso, MD, PhD\u003c\/li\u003e\n\u003cli\u003e2:30PM – 2:45PM CAR-T Cell Therapies Panel Discussion\/Q\u0026amp;A David Faleck, MD (Moderator)\u003c\/li\u003e\n\u003cli\u003e3:00PM – 3:15PM VEGF Tyrosine Kinase Inhibitors and HIF-2 Alpha Inhibitors Martin H Voss, MD\u003c\/li\u003e\n\u003cli\u003e3:15PM – 3:30PM EGFR and ALK Inhibitors Isabel Preeshagul, MD\u003c\/li\u003e\n\u003cli\u003e3:30PM – 4:00PM CDK4\/6 and PI3K Inhibitors Serena Wong, MD\u003c\/li\u003e\n\u003cli\u003e4:00PM – 4:30PM Management of Endocrine Adverse Events James Flory , MD\u003c\/li\u003e\n\u003cli\u003e4:40PM – 4:55PM LAG-3 Inhibitors Michael Postow, MD\u003c\/li\u003e\n\u003cli\u003e4:55PM – 5:10PM Management of Infusion Reactions from ICIs and Other Oncology Agents Autumn C Guyer, MD\u003c\/li\u003e\n\u003cli\u003e5:10PM – 5:25PM Management of Gastrointestinal Immune-Related Adverse Events David Faleck, MD\u003c\/li\u003e\n\u003cli\u003e5:25PM – 5:40PM Management of Cutaneous Immune-Related Adverse Events Alina Markova , MD\u003c\/li\u003e\n\u003cli\u003e5:40PM – 5:55PM Novel Immune Checkpoint Inhibitors (ICIs) Panel Discussion\/Q\u0026amp;A Steven Maron, MD,MSc (Moderator)\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954505879650,"sku":"MED-AMB04886","price":40.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Memorial-Sloan-Kettering-Cancer-Center-Oncologic-Toxicity-Management-Symposium-2025.jpg?v=1779378381","url":"https:\/\/meducourse.com\/products\/memorial-sloan-kettering-cancer-center-oncologic-toxicity-management-symposium-2025","provider":"Meducourse","version":"1.0","type":"link"}